Track-And-Trace Insufficient For Biosimilar Pharmacovigilance, Brand Companies Say

A Johnson & Johnson citizen petition lays out the company’s case for individual non-proprietary names for biologics and each of their biosimilars, citing the risk of inappropriate substitution.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America